Ipilimumab

The addition of nivolumab to ipilimumab conferred a long-term OS benefit for patients with advanced melanoma, according to study results presented at ESMO Congress.

CHICAGO — Individuals with resectable stage III melanoma derived significant EFS benefits with neoadjuvant immunotherapy compared with standard treatment, results from a randomized phase 3 trial presented at ASCO Annual Meeting showed.

CHICAGO — Combination immunotherapy significantly improved outcomes vs. first-line chemotherapy for patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer, according to study results.

CHICAGO — Sequencing encorafenib plus binimetinib with nivolumab and ipilimumab did not delay disease progression in adults with advanced BRAF-mutated melanoma, results from a randomized phase 2 trial showed.

A randomized phase 3 trial that evaluated nivolumab with concurrent chemoradiotherapy for certain patients with advanced lung cancer failed to meet its primary endpoint, according to the agent’s manufacturer.

The addition of nivolumab to ipilimumab significantly improved OS among adults with previously untreated advanced hepatocellular carcinoma, according to a release by the agent’s manufacturer.

In this video, Afsaneh Barzi, MD, PhD, discusses the results of the CheckMate 8HW study.

A phase 2 trial conducted by researchers at The University of Texas MD Anderson Cancer Center demonstrated the safety and potential efficacy of neoadjuvant immunotherapy for patients with soft tissue sarcoma.

NASHVILLE, Tenn. — Patients with renal cell carcinoma who met eligibility criteria for pivotal phase 3 trials achieved significantly longer survival after combination immunotherapy than trial-ineligible patients, according to study results.

Researchers at UT Southwestern Medical Center have introduced a new metric that may be useful in predicting which patients are likely to develop immunotherapy toxicity.